SAN MATEO, Calif.–(BUSINESS WIRE)–BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models and high-speed automated wet labs, today announced a partnership with Eli Lilly and Company (Lilly) focused on advancing machine learning-enabled biopharmaceutical discovery through Lilly TuneLab. This project expands on BigHat's relationship with Lilly, including a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody therapeutics.
Peyton Greenside, CEO and co-founder of BigHat, said, “Current AI/ML capabilities for antibody development capabilities Models have limited ability to generalize to new sequences, largely because antibody development capabilities have been trained on inconsistent and limited formats. As a result, they are primarily used to prioritize among hits, rather than to meaningfully improve development capabilities or inform early impact development decisions.
Lilly launched the TuneLab platform to give biotech companies access to practical AI-enabled drug discovery models. This model requires highly accurate predictions across the diversity of therapeutic antibody candidates despite their diverse biophysical properties. To support TuneLab's continued evolution, BigHat leverages best-in-class ML expertise and the Milliner™ platform to rapidly generate diverse, high-quality datasets suitable for use in generalizable antibody development infrastructure models.
About BigHat Biosciences
BigHat Biosciences is an AI/ML-driven drug discovery and development company that integrates state-of-the-art computational modeling and high-throughput automated wet labs. This integrated platform enables rigorous benchmarking of AI models and rapid experimental validation across biological modalities, targets, and therapeutic areas, enabling differentiated next-generation antibody therapies for patients with profound unmet needs.
Headquartered outside of San Francisco, BigHat is a Series B biotechnology company with a pipeline that includes a next-generation ADC for gastrointestinal cancers that will enter the clinic in 2026 and an avidity-driven TCE for solid tumors that will receive an IND in 2026, in addition to several partnership programs. BigHat has raised over $140 million from leading investors including Section 32, Andreessen Horowitz (a16z), and 8VC.
contact address
media contact
julie bishop
julie@walkercomms.com
